Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

TEVA stock hub

Teva Pharmaceutical Industries Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TEVAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

41.6B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

TEVA

In the news

Latest news · TEVA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E14.4

P25 12.3P50 18.4P75 33.1

Trailing P/E26.7

P25 14.9P50 23.2P75 38.5

ROE21.6

P25 -105.6P50 -46.5P75 -3.1

ROIC18.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TEVA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

257

Groups with data

Currency

USD

Showing 257 of 257 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000818686
Company name	Teva Pharmaceutical Industries Limited
Country	Israel
Country code	US
Cusip	881624209
Employees	33,950
Employees Change	-2,880%
Employees Change Percent	-7.82
Enterprise value	$54.8B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Isin	US8816242098
Last refreshed	2026-05-10
Market cap	$41.6B
Market cap category	Large-Cap
Price	$35.73
Price currency	USD
Rev Per Employee	511,016.2x
Sector	Healthcare
Sic	2834
Symbol	TEVA
Website	https://www.tevapharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.76%
EV Earnings	35.01x
EV Sales Forward	3.18x
EV/EBIT	13.68x
EV/EBITDA	10.95x
EV/FCF	46.75x
EV/Sales	3.16x
FCF yield	2.82%
Forward P/E	14.39x
P/B ratio	5.06x
P/E ratio	26.68x
P/S ratio	2.4x
PEG ratio	3.53x
PS Forward	2.42x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	23.09%
EBITDA Margin	28.84%
FCF margin	6.76%
Gross margin	52.06%
Gross Profit	$9B
Gross Profit Growth	10.56%
Gross Profit Growth Q	5.01%
Gross Profit Growth3 Y	9.84%
Gross Profit Growth5 Y	3.67%
Net Income	$1.6B
Net Income Growth Q	72.43%
Net Income Growth Quarters	5%
Net Income Growth Years	1%
Pretax Margin	7.95%
Profit Margin	9.02%
Profit Per Employee	$46,097
Profitable Years	1
ROA	6.38
Roa5y	4.67
ROCE	15.11
ROE	21.6
Roe5y	-7.19
ROIC	18.63
Roic5y	12.12

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-2.9%
Cagr15y	-0.81%
Cagr1y	103.11%
Cagr20y	0.03%
Cagr3y	59.7%
Cagr5y	28%
Div CAGR10	-4.59%
EPS Growth Q	72.22
EPS Growth Quarters	5
EPS Growth Years	1
FCF Growth	53.2%
FCF Growth3 Y	6.73%
OCF Growth	35.39%
OCF Growth10 Y	-11.11%
OCF Growth3 Y	4.69%
OCF Growth5 Y	27.64%
Revenue Growth	4.41x
Revenue Growth Q	2.34x
Revenue Growth Quarters	5x
Revenue Growth Years	3x
Revenue Growth3 Y	5.14x
Revenue Growth5 Y	1.28x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.44
Assets	$40B
Cash	$3.7B
Current Assets	$13.7B
Current Liabilities	$13.5B
Debt	$16.9B
Debt EBITDA	$3.29
Debt Equity	$2.06
Debt FCF	$14.44
Equity	$8.2B
Interest Coverage	4.48
Liabilities	$31.8B
Long Term Assets	$26.3B
Long Term Liabilities	$18.3B
Net Cash	$-13.2B
Net Cash By Market Cap	$-31.69
Net Debt EBITDA	$2.64
Net Debt Equity	$1.6
Net Debt FCF	$11.25
Tangible Book Value	$-11.2B
Tangible Book Value Per Share	$-9.62
WACC	7.6

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.01
Inventory Turnover	2.59
Net Working Capital	$-951M
Quick ratio	0.53
Working Capital	$178M
Working Capital Turnover	$63.2

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-2.93%
Dividend per share	$0
Dividend Yield	0%
Last Dividend	$0.07

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-25.5%
1Y total return	103.01%
200-day SMA	26.37
3Y total return	307.41%
50-day SMA	31.45
50-day SMA vs 200-day SMA	50over200
5Y total return	243.56%
All Time High	72.31
All Time High Change	-50.59%
All Time High Date	2015-07-28
All Time Low	0.3
All Time Low Change	11,934.36%
All Time Low Date	1988-02-03
ATR	1.11
Beta	0.86
Beta1y	0.87
Beta2y	0.68
Ch YTD	14.48
High	36.33
High52	37.35
High52 Date	2026-02-03
High52ch	-4.32%
Low	35.43
Low52	14.99
Low52 Date	2025-08-01
Low52ch	138.36%
Ma50ch	13.6%
Premarket Change Percent	1.03
Premarket Price	$36.38
Premarket Volume	8,376
Price vs 200-day SMA	35.51%
RSI	68.07
RSI Monthly	74.04
RSI Weekly	67.22
Sharpe ratio	1.86x
Sortino ratio	3.64
Total Return	-2.93%
Tr YTD	14.48
Tr15y	-11.5%
Tr1m	21.82%
Tr1w	2.23%
Tr3m	3%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	2
Analyst Price Target Top	$42
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.46
Earnings EPS Estimate Growth	-11.54
Earnings Revenue Estimate	3,813,796,848x
Earnings Revenue Estimate Growth	-1.98x
Operating Income	$4B
Operating Income Growth	17.07
Operating Income Growth Q	7.62
Operating Income Growth3 Y	17.08
Operating Income Growth5 Y	6.92
Operating margin	23.09
Price target	$42
Price Target Change	$17.55
Price Target Change Top	$17.55

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,083,200,880%
Float Percent	93.02%
Net Borrowing	-469,000,000
Shares Insiders	0.44%
Shares Institutions	71.72%
Shares Out	1,164,426,972
Shares Qo Q	0.51%
Shares Yo Y	2.93%
Short Ratio	5.16
Short Shares	2.57

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$1B
Average Volume	6,735,330.9x
Bv Per Share	7.07
CAPEX	$-542M
Ch10y	-28.92
Ch15y	-24.11
Ch1m	21.82
Ch1w	2.23
Ch1y	103
Ch20y	-17.88
Ch3m	3
Ch3y	307.4
Ch5y	243.6
Ch6m	49.06
Change	-0.78%
Change From Open	-1.46
Close	36.01
Days Gap	0.69
Depreciation Amortization	997,000,000
Dollar Volume	293,730,470.3
Earnings Date	2026-04-29
Earnings Time	bmo
EBIT	$4B
EBITDA	$5B
EPS	$1.34
F Score	7
FCF	$1.2B
FCF EV Yield	2.14x
FCF Per Share	$1.01
Financing CF	-394,000,000
Fiscal Year End	December
Founded	1,901
Goodwill	15,822,000,000
Graham Number	14.6214
Graham Upside	-59.08
Income Tax	$-187M
Investing CF	765,000,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Date	2004-07-01
Last Split Type	Forward
Last10k Filing Date	2026-02-03
Ma150	29.15
Ma150ch	22.56%
Ma20	33.11
Ma20ch	7.92%
Net CF	2,044,000,000
Next Earnings Date	2026-07-29
Open	36.26
Optionable	Yes
P FCF Ratio	35.5
P OCF Ratio	24.27
Position In Range	33.33
Post Close	35.73
Postmarket Change Percent	-1.46
Postmarket Price	$35.21
Ppne	4,333,000,000
Pre Close	36.01
Price Date	2026-05-08
Price EBITDA	$8.32
Relative Volume	1.22x
Revenue	17,349,000,000x
SBC By Revenue	0.96x
Share Based Comp	166,000,000
Tax By Revenue	-1.08x
Tr20y	0.64%
Tr6m	49.06%
Volume	8,220,836
Z Score	0.79

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TEVA pay a dividend?

Capital-return profile for this ticker.

Performance

TEVA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TEVA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+71.7%

Float: +93.0% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TEVA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

68.1

Neutral momentum band

Price vs 200-day MA

+35.5%

50/200-day relationship not available

Beta (5Y)

0.86

Moves roughly with the market

Sharpe ratio

1.86

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TEVA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TEVA stock rating?

Teva Pharmaceutical Industries Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TEVA analysis?

The full report lives at /stocks/TEVA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TEVA?

The latest report frames TEVA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TEVA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.